On September 29, HENGRUI PHARMA rose 3.57% in regular trading, trading at HK$46.1/share, with turnover of HK$34.26 million.

The rally was driven by a wave of institutional accumulation from top global asset managers. UBS Group acquired approximately 2.07 million H-shares on September 21 at an average price of HK$48.86 per share, lifting its long position to 5.23%. BlackRock further increased its stake on September 22 by approximately 1.96 million shares, raising its holding ratio to 7.32%, following a series of earlier additions that pushed its position from 6.56% to as high as 7.68% in mid-September. Capital Group also added roughly 579,000 shares at approximately HK$48.07 per share. Both Citigroup and Bank of America maintained positive ratings on the stock, citing innovation-driven policy tailwinds and global expansion prospects.

Simultaneously, the company has seen an acceleration in clinical trial approvals, with the NMPA recently greenlighting trials for over ten drug candidates including HRS-7172 tablets, SHR-4595 injection for advanced solid tumors, HRS-1596 tablets for weight management and type 2 diabetes, and recaticimab injection for stroke prevention. The company has also been actively executing share buybacks, repurchasing 250,000 A-shares on September 23 for approximately RMB 11.37 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)